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ABSTRACT

CAUSES OF RESISTANT HYPERTENSION IN PATIENTS REFERRED TO A
TERTIARY CARE CLINIC

Marko Yakovlevitch, Henry R. Black,

Section of Cardiology,

Department of Internal Medicine, Yale University School of
Medicine, New Haven, CT

Current estimates regarding the prevalence,
frequency of causes,
with clinical

and the

of resistant hypertension (HTN) vary

setting.

We evaluated 301 consecutive

patients referred to a tertiary care hypertension clinic,
81 of whom were referred by a physician because of
resistant HTN.

Sixty-one (75%)

criteria for resistant HTN:
pressure (BP)

of those patients met our

failure to achieve blood

control with three or more drugs,

and

absence of a known secondary cause at the time of
referral.
The cause of resistant HTN was found in 52 patients
(85%):

suboptimal medical

intolerance in 13,
HTN in 5,
alcohol

regimen in 23, medication

primary noncompliance in 5,

psychiatric disorders in 4,

abuse in 1,

secondary

white coat HTN in 4,

and a drug interaction in 1.

BP control was defined as diastolic BP (DBP)

<

90mmHg

and systolic BP < 140mmHg (<_ ISOmmHg for age > 50 and
< 160mmHg for age > 60).

Control was achieved in 30

(55%)

of those 55 patients who met criteria for resistant HTN
and returned to clinic at least once,
improvement

(_> 15% fall

and significant

in DBP) was achieved in another

six.
In conclusion,

resistant HTN is common in a tertiary

care setting and is most frequently caused by a suboptimal
medical

regimen;

furthermore,

the majority of these

patients can be successfully treated.

Of patients who

were controlled after having been on a suboptimal
61% needed initiation of diuretic therapy,

regimen,

and 52% needed

initiation of therapy with a relatively new agent

(calcium

antagonist or angiotensin-converting enzyme inhibitor).
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1

INTRODUCTION

The prevalence of resistant hypertension,

and the

frequency of the various causes underlying resistance,
will

change as greater information about this condition

becomes available and as more effective therapy is
developed.

Hypertension that is resistant now may not be

considered resistant in the future when more powerful
better tolerated drugs come into wider use.

and

Even now,

hypertension that is considered resistant in some settings
would not be considered resistant in others by virtue of
varying levels of sophistication from one clinic to
another.

Physicians who have not yet begun to use the

newest agents,

or who neglect the oldest ones,

will

encounter resistance where others would not.
Despite variability in the classification of
resistant hypertension,

delineating the characteristics of

patients referred with this diagnosis to a specialty
clinic will help elucidate the reasons for resistance and
enable primary physicians to manage this problem more
successfully.
therapies:

Numerous studies have evaluated potential

calcium antagonists1~5

agents such as felodipine,6-9
enzyme inhibitors,10-15
an experimental
1abetalol28-31

including experimental

angiotensin-converting

vasodilators,16-23

agent), 2 4 - 2 5

doxazosin (also

furosemide, 2 6 - 2 7

and

have all shown some effectiveness in the
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treatment of "resistant hypertension."
There are very few epidemiological studies of
resistant hypertension,

and it is commonly held that

resistant hypertension is very unusual.32”34
which supports this view was reported in 1988;

One study
the authors

sought to determine what proportion of an employed
hypertensive population have resistant hypertension.32
1,781 hypertensive patients,
resistant,
years.

Of

only 2.9% were found to be

and 63% of those were controlled in subsequent

Since there was some component of noncompliance in

14 of the 19 patients who remained resistant,

the

investigators concluded that the incidence of resistance
was 0.3%.

However,

this population of employees who were

identified by workplace screening and who elected on-site
treatment is not representative of the general population
of hypertensive patients.

It should also be noted that

diagnosing a cause of resistance,

such as noncompliance,

does not necessarily ensure ability to control blood
pressure.

For this reason,

I would still

categorize

noncompliant patients with uncontrolled hypertension as
resistant to therapy.
education,

A noncompliant

a simplified regimen,

patient requires

and possibly other

therapeutic interventions before blood pressure becomes
controllable;

therefore noncompliance is a form of

patient-derived resistance.
The goals of the present study are to determine:

3

1) The frequency of resistant hypertension in a tertiary
care clinic.
2) The medical

regimens employed by the referring

physician in those patients.
3) The frequency of causes of resistance,

including

curable secondary causes.
4) The proportion of patients meeting criteria for
resistant hypertension who can ultimately be
controlled,

and the intervention required.

This information will

then be used as the basis for a set

of guidelines for the evaluation of patients with
resistant hypertension.
A set of categories for resistant hypertension is
presented below using a modification of the schema
proposed by Frohlich.35

A)

Patient-derived resistance
1) Patient is unable or unwilling to tolerate side
effects.

Excluded from this category are

disease-related side effects,

such as medically

unacceptable cardiovascular or renal

side effects

which the patient's physician needs to avoid through
the selection of appropriate drugs.
2) Noncompliance with the therapeutic regimen.

This is

believed by some investigators to be among the most
likely dominant causes.32'36

4

3)

Psychological

causes such as panic attacks in

patients with anxiety disorders,

or subjective

medication intolerance resulting from the
misinterpretation of physical

and/or psychological

stimuli as side effects of medication.
B) Physician-derived resistance
1) Failure to identify drug interactions,
that can arise from nonsteroidal
drugs and oral

such as those

anti-inflammatory

contraceptives.33'35'37

2) Failure to identify hypertension-promoting drugs or
behaviors

(such as alcohol

abuse)

and to educate the

patient to modify such behaviors.37-39
3) Use of a suboptimal medical

regimen.

a) Use of suboptimal dosages of standard
medication in the absence of dose-1imiting
side effects or patient intolerance.
also believed to be among the most

This is

likely

dominant causes.36
b) Failure to prescribe standard medication or
inappropriate choice of medication.
example,

For

failure to prescribe diuretics in

patients with volume-dependent hypertension,
and failure to substitute loop diuretics for
thiazides in patients with renal
insufficiency.40 »41
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4) Failure to identify and treat correctable secondary
causes of hypertension,
stenosis,

such as renal

pheochromocytoma,

artery

and primary

aldosteronism.
C) Disease-derived resistance
Resistant essential hypertension in a compliant
patient who fails to be controlled with optimal
dosages of three concurrently administered
antihypertensive agents.
D) Pseudoresistance
1) White-coat hypertension:

normotension outside of

the clinic setting.
2) Pseudohypertension:

normal

intra-arterial blood

pressures in a patient with sclerotic brachial
arteries.

This study was designed to test the hypothesis that
resistant hypertension is not an uncommon reason for
referral

to a tertiary hypertension clinic,

and that a

large proportion of the patients referred for resistant
hypertension have been on a suboptimal medical

regimen.

We have defined resistant hypertension as uncontrolled
blood pressure despite attempted therapy with at

least

three antihypertensive agents in a patient who is
considered resistant by a referring physician.
for blood pressure control

Criteria

are outlined in table 1.
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Table 1.

Criteria for blood pressure control.

Systolic blood pressure
Diastolic blood pressure

<.50

Acre (years)
51 - 60

> 60

<.140
£ 90

< 150
<_ 90

< 160
£ 90

The criteria for blood pressure control

are based

upon a goal blood pressure independent of the blood
pressure on referral;

this contrasts with the definitions

accepted by some other investigators.32'37

Predicating

loss of resistance on the achievement of blood pressure
control,

rather than on a proportionate lowering of blood

pressure,

is in keeping with the aims of antihypertensive

therapy.

Even blood pressures that are moderately

decreased from their initial
high;

levels can be unacceptably

patients who have elevated blood pressures should be

considered resistant to therapy because the goal
therapy is to control, not merely to affect,
pressure.

of

blood

7

PATIENTS AND METHODS

Enrollment

The charts were sought of all patients whose initial
visit to the Yale Hypertension Clinic was made between
January 1,

1986 and March 30,

1988.

the clinic attending physician,

In consultation with

each patient was

categorized as to the source of the referral,

and

self-referred patients were distinguished from those who
were referred by a physician.

Those patients who were

physician-referred were further categorized according to
the reason for their referral.
The study group was composed of those patients who
were physician-referred for assistance with the management
of "resistant hypertension," and who did not have an
identified secondary cause for resistance at referral.
The patients from that group who had been tried on at
least three antihypertensive agents and whose blood
pressure was not controlled on their initial visit to the
hypertension clinic (according to the criteria in table 1)
were studied in detail.

Evaluation and Follow-up

Standard initial

evaluation for all patients included

a complete medical history,

past medical history,

physical

8

examination,

and laboratory studies

(unless recent

laboratory data was provided by the referring physician).
Initial

laboratory evaluation in most patients included a

urinalysis,
potassium,

complete blood count,
calcium,

creatinine,

measurement of serum cholesterol

determination of serum

and glucose,

and

and triglyceride levels.

Further laboratory evaluation for secondary causes of
hypertension was pursued when history,
examination,
clinical

physical

or routine laboratory evaluation raised the

suspicion of such.

The criteria used for

initiation of studies for particular secondary causes have
been described elsewhere.42
Dosages of antihypertensive medications were
interpreted according to the dosage guidelines given in
the 1984 Report of the Joint National Committee on
Detection,
Pressure;43
report,

Evaluation,

for newer agents not included in the 1984

the 1988 report38

this is indapamide,
report;

and Treatment of High Blood

was used.

The only exception to

which was not included in either

dosage guidelines for indapamide were taken from

the 1988 Physician's Desk Reference.44
All blood pressures reported in this study are an
average of two readings
taken on the same visit,

(one supine and one standing)
unless the patient's position

during measurement is stated along with the pressure
which case a single reading is being reported).

(in
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Achievement of blood pressure control was defined as
controlled blood pressure on two consecutive visits or on
the final

clinic visit without unacceptable or intolerable

side effects.

The only exception to this is demonstration

of normotension by 24 hour ambulatory monitoring,

with

greater than 85% of blood pressure readings recorded in
the normotensive range (according to the criteria in
table 1).

In the context of elevated clinic pressures,

this established the diagnosis of white-coat hypertension.
Blood pressure was considered "significantly improved" if
there was at

least a 15% fall

in diastolic blood pressure

(the average of two readings on the final visit compared
with the average of those on the initial visit).
Patients were followed until
was less than or equal

systolic blood pressure

to 140mmHg and diastolic blood

pressure was less than or equal

to 90mmHg,

documented by ambulatory monitoring.

or control was

Those patients in

whom blood pressure control was not achieved were followed
until

their last clinic visit.

Final Diagnosis

The criteria for the diagnosis of specific causes of
resistance are as follows:

Patient-derived resistance
Multiple medication intolerance:

inability to
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achieve therapeutic levels of antihypertensive
drugs without intolerable side effects despite
multiple attempts with a variety of agents.
Noncompliance:

patient acknowledgement during

interview in a consistent clinical
Psychological
1)

setting.

causes:

Symptoms of panic disorder with episodic
elevations in blood pressure.

2) Misinterpretation of psychological
physical

and/or

stimuli as side effects of medication,

resulting in subjective but non-physiological
medication intolerance.
Physician-derived resistance
Alcohol

abuse:

temporal

correlation of blood

pressure resistance with high alcohol
(at least 1.5 ounces of ethanol,
drinks,

consumption

or two average

per day) such that blood pressure came

under control

only with abstinence from alcohol.

Suboptimal medical

regimen:

submaximal dosages of

antihypertensive agents and/or failure to
prescribe an indicated agent.
Secondary causes:
1) Renal

artery stenosis:

positive angiographic

findings in the context of abnormal

captopril

renal scintigraphy and a consistent clinical
setting.
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2)

Primary aldosteronism:

positive urinary

aldosterone studies under a scrupulous
protocol, which has been described elsewhere,44
in a consistent clinical

setting.

Surgery is

pursued when the cause is presumed to be an
aldosterone producing adenoma,

and in those

cases provides the opportunity for pathological
confirmation.
3)

Pheochromocytoma:

positive urinary

catecholamine studies,

with positive magnetic

resonance imaging and/or consistent
pathological

findings in a surgical specimen.

Pseudoresistance
White-coat hypertension:

normotension outside the

clinic setting confirmed by 24-hour ambulatory
monitoring, with greater than 85% of blood
pressure readings in the normotensive range
(according to the criteria in table 1).

Statistical Methods

All means are arithmetic means,
x +. y,
sample.

and when reported as

the y value is the standard deviation of the
Means were compared using critical

calculations

(student's t-test).

ratio

Categorical data was

analyzed with chi-square calculations when E (expected
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value)
met,

for each cell was > 5;

if this condition was not

then Fisher's exact test was used.

for statistical

The requirement

significance was set at p < 0.05,

values are reported only when p < 0.10.

and p

When p > 0.10,

the result is reported as "statistically insignificant."

Ethical

Controls

The protocol

for this study (HIC # 4892) was approved

by the Human Investigation Committee of the Yale
University School

of Medicine.
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RESULTS

Demographic Data and Initial

Evaluation

301 new patients were seen at the Yale Hypertension
Clinic between January 1,

1986 and March 30,

1988.

The

charts of all but one of these patients were recovered and
reviewed.

The sources of,

and reasons for,

referrals are outlined in figure 1.

Figure 1.

Sources of, and reasons for, referrals.

301 new patients
^--*-l chart lost
300 patients whose charts were reviewed
^-> 63 self-referred
^ r'

237 physician-referred
's-->16 referred for problems other than hypertension
221 referred for hypertension
-► 30 referred for primary therapy of hypertension
191 referred for assistance with management of hypertension
v->110 without "resistant hypertension"

I
81 referred for assistance with "resistant hypertension"
7 referred with a known secondary cause
74 referred without a known secondary cause for resistance
v-»-13 judged not to be resistant
k

61 met criteria for resistant hypertension

their
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Of the 74 patients referred for "resistant
hypertension" without a known secondary cause,

six (8%)

had had a complete work-up for common secondary causes of
hypertension prior to their referral,
had had a limited work-up,
Sixty-one patients
hypertension,

and 35

33 patients

(47%)

(45%)

had none.

(82%) met our criteria for resistant

and they comprised the study group.

Their

demographic and baseline clinical data are presented in
table 2.

Neither age,

gender,

or race,

correlated

significantly with whether or not a patient satisfied our
criteria for resistance.
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Table,h_Demographic data.
Range
Age
Female
White
Black
Asian

58
34
51
6
1

+ 15
(56%)
(88%)
(10%)

Smoking history
Current smokers
Alcohol history*
Current alcohol*
Family Hx. HTN

36 (59%)
14 (23%)
3
2
33 (54%)

29-85

Hx. of HTN (years)
Highest SBP by Hx.
Highest DBP by Hx.

15 + 11
205 + 36
118 119

0.2- 50
138-300
70-170

Supine SBP
Supine DBP
Standing SBP
Standing DBP

181
103
178
106

130-240
60-140
122-246
60-150

+
t
+
♦

24
15
28
17

♦Consumption of at least 1.5 ounces of ethanol
(two average drinks) per day.
Abbreviations: Hx. = history, SBP = systolic
blood pressure (in nig), DBP = diastolic blood
pressure (in xxnHg), HTN - hypertension.

The incidence of other medical
patients is reported in table 3.

conditions in these

Coronary artery disease

was established by a history of typical
electrocardiographic,
evidence of ischemia.
controlled as well

radionuclide,

angina and/or

or other objective

Diabetes mellitus included diet-

as insulin-dependent diabetic patients.

Seven of the 13 patients with known renal parenchymal
disease had renal

insufficiency at the time of referral.
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No patient had a history of pheochromocytoma,
aldosteronism,

Table 3.

primary

or congestive heart failure.

Comorbid diseases.
Patients

History of myocardial infarction
Coronary artery dis. without MI*
Diabetes mellitus
Renal parenchymal disease
Renal failure
Renal artery disease**
History of gout
History of hyperthyroidism
Medically treated anxiety

3
6
12
13
0
1
3
3
10

Ho comorbid disease
One comorbid disease
Two comorbid diseases
Three comorbid diseases

23
27
9
2

♦Patients with coronary artery disease without
a history of myocardial infarction.
**Hemodynamical1y insignificant renal artery
disease.

The drugs being used at the time of referral

in these

patients'

regimens are enumerated in table 4

column).

The mean number of agents in those regimens was

2.3 + 1.1.

In this and all

("INITIAL"

subsequent tables,

labetalol

has been included in the category "beta-adrenergic
blockers."

These patients also had a history of having

been tried on 4 + 3 agents

(on average)

that were

discontinued because of side effects or ineffectiveness.
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Table 4. Frequency of medication use and adiustment of medical regimens.
H = 61
INITIAL

Agent

FINAL

Added
22
12

Diuretics
Thiazides
Thiazide/Potassium-sparing**
Loop diuretics
Potassium-sparing
Indapamide

36
16
6
10
3
1

36
19
8
8
1

Beta-adrenergic blockers
Central-adrenergic inhibitors
Reserpine
Alphai-adrenergic blockers

33
11
1

22
3
1
“

5

3
31
30

Vasodilators
ACE inhibitors
Calcium antagonists

34
19

-

N = 49*
Removed Increased Decreased

5
2

4
1

-

-

3
-

2
1
“

10
8

4

1

-

1
“

1

-

-

1
11
18

-

-

6
1

3

5

5

3

5
5
0
“
4

-

10
3
1
3
2
1

-

1

‘Does not include patients with alcohol abuse or a secondary disease causing resistance.
“Fixed combination agents.
Abbreviations: Thiazides = Thiazides and related sulfonamide diuretics,
Potassium-sparing = Potassium-sparing diuretics, ACE = Angiotensin-converting enzyme.

Mean cholesterol
in 46 patients,
respectively.

and triglycerides levels, measured

were 226 +. 45mg/dL and 174 +_ 96mg/dL
Mean HDL and LDL levels, measured in 19 and

18 patients respectively,

were 42 +_ 13mg/dL and

152 +. 44mg/dL.

Follow-up and Outcome

Of those 61 patients who met criteria for resistant
hypertension,

55 returned to clinic at least once,

and

18

these comprised the group of resistant hypertensive
patients who were analyzable;

they were followed for an

average of 10.0 _+ 9.3 months.

The final diagnoses along

with the results of treatment in the clinic are summarized
in figures 2 and 3.

Patients were assigned to categories

of causes of resistance based upon their meeting the
specific criteria stated under "Final Diagnosis."
cases,

In some

patients met the criteria for more than one cause.

When both of these causes were important contributors to
resistance,
category;

the patient is reported in a combined

when one was a minor contributor to resistance,

the patient is reported in the major category alone.
Minor causes are reported in a footnote of figure 2.
Of those 55 patients who returned to clinic at least
once,

30

(55%) were controlled,

and another 6 had

significantly improved blood pressure.
19,

diastolic blood pressure was

decreased in 9.

All

Of the remaining

(not significantly)

three patients with renal

stenosis responded to angioplasty or surgery,

artery
and both

patients with primary aldosteronism were treated
surgically.
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Figure 2.

Diagnoses and results of treatment.

61 patients with resistant hypertension
^—» 6 seen only once (did not return to clinic)
4

46 patients

Controlled:
Significantly
improved:
Neither:

1

1

16

25

4

6

1

15

*In addition to the primary problems enumerated above, six patients had a suboptimal medical regimen,
three patients had a drug interaction, and two patients had noncompliance as significant but minor
contributors to their resistance.
**Blood pressure control was documented in all but one of the six patients with secondary causes or alcohol
abuse; one of the patients with renal artery stenosis was off all medications after angioplasty and had a
blood pressure of 138/lOOmnHg on her final clinic visit. The three patients without a clearly established
cause of resistance did not show significant improvement in blood pressure control.
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Figure 3,

Frequency of types of resistance.

Table 4 also reports agents used in the final

regimen

of those 49 patients without a curable secondary cause or
alcohol

abuse causing refractory blood pressures

(that is,

those 49 patients with essential hypertension) who
returned to clinic at least once ("FINAL” column).
mean number of agents used was 2.6 +_ 1.3.

The

The therapeutic

interventions according to class of antihypertensive agent
used are also recorded in table 4.
were added and 36 were removed,
agents were increased in dose,

Fifty-seven new agents

while 17 of the original
and 14 were decreased.

Of the 29 patients who were found to have a
suboptimal medical
minor)

regimen as a cause (either major or

for their resistance,

twenty-eight achieved control

or significant improvement in their blood pressure.
those 23 patients who were completely controlled,
agents were added and 14 were removed,

In

32

while 11 of the

21

original

agents were increased in dose,

decreased.

The specific agents

and 9 were

(by class)

are reported in

table 5.

Table 5.

Correction of suboptimal regimens.

Added

Agent
Diuretics
Thiazides
Thiazide/Potassium-sparing*
Loop diuretics

17
10
3

N = 23
Removed Increased Decreased
2
1

2

4

3
1
1
1

1

2

Beta-adrenergic blockers
Central-adrenergic inhibitors
Reserpine

1
1

5
4
“

3

1

Vasodilators
ACE inhibitors
Calcium antagonists

1
3
9

2

2

1
3
2

4

*Pixed combination agents.
Abbreviations: Thiazides = Thiazides and related sulfonamide diuretics,
Potassium-sparing = Potassium-sparing diuretics, ACE - Angiotensin-converting enzpe.

Of the 23 patients who were on a suboptimal medical
regimen and were subsequently controlled,

21

(91%) needed

the addition of one or more new agents to their regimen.
Fourteen of these 23 patients

(61%) needed initiation of

diuretic therapy to achieve control,

and another three

patients needed a change in diuretic agent

(one from a

loop diuretic to a thiazide,

two from a thiazide to a loop

diuretic).

(70%) needed initiation or

Sixteen patients

22

augmentation of therapy with a relatively new agent:
calcium antagonist

a

(12) and/or an angiotensin-converting

enzyme inhibitor (5).

Some patients needed an increase in

the dosage of medication they were already taking.

Of

those 29 patients who were on a suboptimal medical
regimen,

thirteen (45%) were controlled by the addition,

or augmentation,

of diuretic and/or calcium antagonist

therapy alone.
Noncompliance (as a major or minor contributor to
resistance) was present in sixteen patients;

it was

accompanied by medication intolerance in nine.

The

patients who did not have accompanying medication
intolerance were more likely to show significant
improvement in blood pressure than those who did
(0.05 <. p <_ 0.10).

In those seven patients who had

noncompliance without medication intolerance,

the three

whose regimen was increased in frequency did not have
significant improvement in blood pressure;

the four

patients whose regimen was decreased in frequency or
unchanged,

did have significant improvement

(p < 0.05).

Frequency of a patient's regimen was defined as the
frequency of the most frequently taken agent on that
regimen.

Covariate Analysis

Final

outcome (controlled vs.

not controlled,

and

23

controlled or significantly improved vs.
correlate with age,

gender,

race,

neither) did not

presence of particular

comorbid diseases, number of comorbid diseases,
use (prior or present),
present),

high alcohol

duration of hypertension,

triglyceride, HDL,

and LDL levels,

tobacco

consumption (prior or
cholesterol,

or highest blood

pressures by history (systolic or diastolic).

There was a

trend towards higher diastolic blood pressure (by history)
in those patients who could not be controlled:
115 + 18mmHg,

controlled

controlled or significantly improved

116 +. 19mmHg, no significant improvement 122 +_ 17mmHg;
however,

the difference was not statistically significant.
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DISCUSSION

Resistance to therapy is a subjective experience as
well as an objective phenomenon.

Thus,

it is not

surprising that some patients who are referred for
resistant hypertension will not meet objective criteria
for such.

The criteria used for inclusion in this study

were designed to identify those patients who can be
justifiably called resistant by a referring physician.
The high frequency of resistance found in this clinic
population (20% of 300 patients)

is in marked contrast to

the recent study of employed hypertensive patients
identified by workplace screening which found a less than
3% incidence.32

However,

the investigators in that study

removed from the "resistant” category all patients who
achieved a 10% fall

in diastolic and 15% fall

in systolic

blood pressure even if final blood pressure remained above
normal.

I disagree with this criterion of categorization

because those patients still have unacceptable blood
pressures in spite of medical

therapy,

and are therefore

resistant to attempts at controlling blood pressure even
if they aren't resistant to attempts at improving it.

It

has been suggested previously that severe resistant
hypertension may be present in 5 to 10% of hypertensive
patients45

and,

with clinical

as this study shows,

setting.

the frequency varies

The frequency of resistance varies

with both the clinic's population and the clinic's level
of expertise in treating the condition.
Of the 61 patients who met criteria for resistant
hypertension upon referral,

24 still had resistant

essential hypertension at the conclusion of the study.
This means that eight percent of patients seen in this
tertiary care clinic continued to have uncontrolled blood
pressure (by the criteria in table 1)
or most recent,

clinic visit.

Thus,

through their final
I would say that in

the population of patients seen in this hypertension
clinic,

20% had hypertension resistant to community care,

and eight percent had hypertension resistant to expert
care.

The majority of patients in this latter group had

medication intolerance or noncompliance causing
resistance.
These patients referred for resistant hypertension
had (on average)

a 15 year history of documented disease,

with an average of four drugs having been tried and
discontinued in the past because of side effects or
ineffectiveness.

Nonetheless,

the most frequent cause of

resistance in the community setting was a suboptimal
medical

regimen.

Almost half the patients referred for

resistant hypertension were found to have resistance due
to a suboptimal medical

regimen,

and three-quarters of

those patients could subsequently be controlled.

In fact

all but one of those 29 patients who were on a suboptimal
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regimen achieved at least a 15% fall
pressure if not complete control
pressures.

in diastolic blood

of systolic and diastolic

Addition of a diuretic or use of a newer agent

such as a calcium antagonist,
with these agents,

or augmentation of therapy

proved to be the most successful

therapeutic maneuver in this group.
Angiotensin-converting enzyme (ACE)
added in a few patients.

All

inhibitors were also

the interventions used were

ones generally available to outpatient clinics.
The need for calcium antagonists in patients referred
on suboptimal

regimens is probably due to less familiarity

among referring physicians with these agents. ACE
inhibitors,

which are a few years older than calcium

antagonists, were added less often.

Fifty-seven percent

of patients who met criteria for resistance at referral
were referred on ACE inhibitors, while calcium antagonists
were used in only 31%.

Treatment in the Hypertension

Clinic eliminated the difference; ACE inhibitors were used
in 65% of patients with essential hypertension,
calcium antagonists were used in 61%.

and

Use of these agents

frequently permitted discontinuation of agents that carry
more side effects,

such as central-adrenergic inhibitors

and beta-adrenergic blockers.
The high frequency of inadequate diuretic therapy may
reflect a growing reluctance to use these agents because
of the criticism they have received with time.

Avoiding
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diuretics in favor of newer agents causes problems in
patients with volume-dependent hypertension, which is
particularly common among patients taking peripheral
alphai-adrenergic blockers,
vasodilators,

central

alpha2

agonists,

or peripheral sympathetic blockers.46

The

need to adequately control volume in hypertensive patients
cannot be overemphasized,
prevent control

for volume overload alone can

of otherwise manageable

hypertension;26'27'41
as "pseudotolerance"35

this phenomenon has been referred to
or "pseudo-resistance"46.

Five patients were referred on vasodilator therapy.
Two of those did not return to clinic,

and a third

returned only once and was lost to follow-up before a
diagnosis was established.

The vasodilator dosage was

halved in one of the two remaining patients,
discontinued in the other.

and it was

Only one patient was started

on vasodilator therapy in the Hypertension Clinic (in this
case, with minoxidil).

This patient was intolerant of

other agents when they were prescribed at dosages that
controlled blood pressure.

In summary,

only two patients

were taking minoxidil at the conclusion of the study.
Minoxidil

is an effective but poorly tolerated treatment

for resistant hypertension16'18'21'47
present study,

and,

as shown in the

is rarely needed now that ACE inhibitors

and calcium antagonists are available.
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Secondary causes of hypertension,
in the general population,
this referred group.

were certainly not uncommon in

Of patients meeting our criteria for

resistant hypertension,
secondary causes.

though not common

eight percent had correctable

However,

the seven patients who were

referred with a known secondary cause were excluded from
the present study; when these patients are included,

the

incidence of secondary hypertension becomes 15% of
patients referred to the clinic for "resistant
hypertension."

The Cleveland Clinic has reported an 11%

incidence of secondary hypertension among 4,939 patients
referred to the clinic with hypertension (not necessarily
resistant)

over a two year period.48

Other sources have

reported a 0.5 to 10% incidence of secondary
hypertension;42

the broad range arises from variability in

the kind of populations studied.
The five percent incidence of renal artery stenosis
is similar to that reported by a study of 3,520 patients
referred for evaluation for secondary causes of
hypertension, which found a three percent incidence,49
well

as

as the four percent incidence found in the Cleveland

Clinic study mentioned above.48
Pheochromocytoma and primary aldosteronism are
reported to have an incidence of 0.1 to 0.5%42'48
hypertensive population.

Therefore,

in a

finding no patients

with pheochromocytoma is consistent with what we would
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expect,

but finding two patients

(three percent) with

primary aldosteronism is a little surprising.

Although

the suggestion of a 20% incidence of "normokalemic
aldosteronism” in patients with ’’essential hypertension”
made by Conn50

has been rejected as a lack of appreciation

of the syndrome of low renin essential hypertension,42
estimates of the incidence of primary aldosteronism may
suffer from underdetection owing to the difficulty in
diagnosing this condition.
in this study,

however,

The small

size of that group

limits the generalizabi1ity of the

findings.
Medication intolerance secondary to psychological
causes was distinguished in this study from medication
intolerance per se.

This was done because patients with

medication intolerance per se had usual side effects from
their antihypertensive drugs,

but of a magnitude and

frequency that prohibited the use of therapeutic dosages.
Those patients who were categorized as having intolerance
secondary to psychological

causes consistently ascribed to

their medications adverse effects which were considered a
result of unrelated psychological

and physical stresses.

Finding an acceptable regimen in these patients is
particularly challenging since the intolerance seems
largely unrelated to the particular agents prescribed.
The majority of patients whose blood pressure could not be
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controlled in the Hypertension Clinic had medication
intolerance and/or noncompliance causing their resistance.
Noncompliance was surprisingly underrepresented as a
cause of resistance;

current estimates of noncompliance

have been as high as 50%,51'52

and as

patients on simplified regimens.53

low as 4% in

It may be that those

patients willing to pursue treatment in a specialty clinic
are more likely to be compliant.

It is also likely that,

with the growing awareness of this problem,
of undetected noncompliance is falling.

the incidence

Slightly more

than half of those patients with noncompliance also had
medication intolerance.

Education alone may be of limited

value in these patients since their noncompliance is
related to poor tolerance of the agents themselves.

These

patients should be considered separately from those
without medication intolerance since one is likely to use
different treatment strategies for the two groups.
Minimizing dosages and taking the liberty to try a variety
of agents may be the most useful

course of action in the

patients with medication intolerance and noncompliance,
while simplification of the medical
most successful

regimen may be the

approach in the patients without

medication intolerance.
The results in this study show a significant
correlation between more complex regimens and failure of
therapy.

An earlier study of compliance in elderly
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hypertensive patients also found that compliance improved
with reduction in the number of tablets taken,
frequency.53

and their

Other research has suggested that failure in

understanding is the most frequent problem in noncompliant
patients;54'55

careful

counseling is an important part of

these patients’ management.

Compliance was assessed in

this study by patient interview,
as pill

which is not as accurate

counts or pharmacist logs,

but is probably still

quite reliable.56
White-coat hypertension was identified in four
patients.

They all

required antihypertensive therapy to

achieve ambulatory normotension,

thus they had essential

hypertension without true resistance.

I categorize

white-coat hypertension as pseudoresistance because it is
not resistance in the hypertension itself,
resistance of a physiological
Pickering calls,

but rather is

anxiety response:

what

"a pressor response to the physician."57

Although 24-hour ambulatory monitoring of every patient is
currently prohibitive, blood pressure measurements at
home,

or in other settings, may provide clues that a

patient has white-coat hypertension,

as might signs of

unusual variability in blood pressure.
Three patients remained undiagnosed.
are potentially disease-resistant cases,

Although these
they were all

lost to follow-up after only two or three visits.

It is
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likely that a cause would have been found if they had
continued to come to the clinic.
Diastolic blood pressure control has been defined as
pressure <_ 90mmHg in other studies24'25

besides this one,

though some authors have used 95mmHg14'23
lOOmmHg. 3 5 - 5 8 _60
ceiling,

In this study,

since this is the level

or

90mmHg was accepted as a
of diastolic control

that

is believed to be associated with decreased morbidity and
mortality.38

Systolic blood pressure control was adjusted

for age to accommodate for isolated systolic hypertension
in the elderly.
160mmHg35

Rather than use a cut-off of 150mmHg60

regardless of age,

or

as has been suggested in some

discussions of resistant hypertension,

the definitions

were chosen to reflect goals that would be systematic and
yet individualized.
Using an average of two blood pressure measurements
when assessing for blood pressure control serves two
purposes.

Firstly,

it decreases the variability

associated with single measurements;

it is for this reason

also that two consecutive visits with controlled blood
pressure were required to establish loss of resistance.
Secondly,
pressures,

being an average of supine and standing blood
it assures that supine blood pressure is

controlled within the limits tolerated by standing blood
pressure.

Supine blood pressure control

to achieve because of postural

changes,

can be difficult
but it should be

included in the definition of control

since target organ

damage may progress when only supine blood pressure
remains uncontrolled.61
The criteria for demonstrating control

of

hypertension included cases of demonstratiion of control
on only a single visit if that was the patient's final
visit to the Hypertension Clinic.

This condition was

included because,

clinic,

being a referral

patients were

often not seen after control was achieved.

Accepting a

final visit blood pressure as evidence for control helped
eliminate the bias introduced by discounting as
uncontrolled all

those patients who did not return becaus

their hypertension became controlled.
The size of the sample in this study limited the
likelihood of demonstrating associations between factors
which may be identified on an initial visit and the final
categories of resistance (or outcome).

Factors that may

be associated with particular categories of resistance
according to a previous study include gender,
pressure,

body mass index,

cholesterol,
age,

race,

funduscopic changes,

and fasting blood sugar.32

smoking history,

blood
serum

As in this study

and a history of angina were

not found to be significantly associated with final
diagnosis.

Other studies have shown particular agents to

be more effective in certain subpopulations.

For example
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diltiazem seems to be more effective in older and female
patients.6 2
I would conclude from the present study that
resistant hypertension,

the reason for referral

in 26% of

physician-referred patients in this tertiary care clinic,
is not unusual.

Excluding drug interactions and

noncompliance is the first step in managing these
patients;

likewise, white-coat hypertension and

pseudohypertension should be considered at the outset.
The large majority of those patients remaining resistant
are likely to be on suboptimal medical

regimens,

be controlled with changes in their regimens.
patients will be volume expanded,

and can

Many

and most will

require

the addition or augmentation of appropriate diuretic
therapy;

some will

require adjustment of diuretic therapy,

such as replacing thiazides with loop diuretics in
patients with renal

insufficiency.

Although calcium

antagonists were also important in achieving control,

the

need for this intervention probably reflects the time lag
between the introduction of new agents and their
widespread use.

Evaluation for secondary causes of

hypertension will

identify curable diseases in some of the

patients who remain resistant.

Those remaining patients

without a secondary cause will

typically be resistant as a

result of medication intolerance with or without
noncompliance.

These two problems are often interrelated

and difficult to correct.

Simplifying regimens and

minimizing adverse side effects will provide some degree
of success with these patients.

An algorithm for the

management of patients with resistant hypertension
follows;

it is an adaptation of a schema presented

elsewhere by Black.46

1.

Exclude drug interactions and noncompliance.

2.

Be sure the patient doesn't have white-coat
hypertension or pseudohypertension.

3.

Be sure the patient isn't volume expanded.

4.

Evaluate the patient for secondary causes of
hypertension.

5.

Simplify the regimen,

if possible,

and minimize

adverse side effects.

Although the patients referred to a tertiary care
clinic represent a biased population of hypertensive
patients,

the present study offers some suggestions as t

approaches that may be productive and effective in
patients with resistant hypertension,

and also provides

another perspective on the frequency of resistant
hypertension and its subtypes.
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